Search Results for: 창원출장안마【KaKaotalk:ZA32】200%보장 전지역 모두 출장가능길음역텍사스위치무주
Nothing Found
Sorry, but nothing matched your search terms. Please try again with some different keywords.
DOWNLOAD RESEARCH REPORT
And a Door Opens Wide
Antisense Therapeutics’ lead drug sits at the nexus of two areas of drug development that are starting to grow dramatically in importance. One relates to its mode of action and the other to the type of drug it is. Combine that with management who know the drug very well and strong results in a trial in a horrible disease afflicting children, and you have the basis for true value creation.
DOWNLOAD RESEARCH REPORT
A Laser-Like Focus on Adding Value
Since August 1st, Kazia Therapeutics has announced US Food & Drug Administration fast track status for one program & orphan drug and rare paediatric disease designation for another, while finishing the period by announcing a new trial for its cancer drug, paxalisib. Over the next nine months investors are likely to see six data readouts from five programs. How fast can a company go?
DOWNLOAD RESEARCH REPORT
Fit for tough times; prepared for coal’s upswing
Terracom has counter-cyclically placed itself in a position to improve efficiency and margins plus pursue organic mine growth. Cashflows will further swell once currently depressed coal prices rebound. These assets appear undervalued compared to our Base Case $0.27/share NPV valuation of TER. TER has upside on management’s record of delivering new projects from currently controlled development assets and/or by opportunistically securing acquisitions.
